Sanofi
CIK 1121404 · last filed 2026-08-12
Sanofi is a corporate insider who has filed 68 SEC Form 4 insider transactions across 13 companies since 2011. The most recent filing, for LTGO, was dated Aug 12, 2026. Across all open-market trades the lifetime net is −$2.43B, making them a net seller over the disclosed history. Current disclosed insider exposure totals $10.05B across reported positions. 70 SEC filings were submitted jointly with REGENERON PHARMACEUTICALS, INC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$10.05B
13
68
-$2.43B
Filer Profile
PARIS, I0 75017
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) Delisted | 10%+ Owner | 494,800 | — | — | $0 | 1 | 2026-08-12 |
| ATTO | 10%+ Owner | 1,082,855 | $22.79 | $24.68M | $10.20M | 2 | 2026-08-07 |
| Translate Bio, Inc. (TBIO) Delisted | 10%+ Owner | 3,064,003 | $0.00 | $306 | $2.74B | 1 | 2021-09-14 |
| Icosavax, Inc. (ICVX) Delisted | 10%+ Owner | 3,155,169 | $15.31 | $48.31M | $1.00M | 1 | 2021-08-02 |
| Inozyme Pharma, Inc. (INZY) Delisted | 10%+ Owner | 438,875 | $4.00 | $1.76M | $1.30M | 1 | 2020-07-29 |
| REGN | 10%+ Owner | 279,766 | $781.49 | $218.63M | -$9.52B | 46 | 2020-06-11 |
| FULC | 10%+ Owner | 464,285 | $3.80 | $1.76M | $1.50M | 1 | 2019-07-23 |
| MyoKardia, Inc. (MYOK) Delisted | 10%+ Owner | 0 | — | — | -$121.48M | 5 | 2019-02-15 |
| ALNY | 10%+ Owner | 10,554,134 | $248.68 | $2.62B | $1.98B | 6 | 2017-06-01 |
| VYGR | 2,352,941 | $3.19 | $7.51M | $1.75M | 1 | 2015-11-18 | |
| Regulus Therapeutics Inc. (RGLS) Delisted | 10%+ Owner | 42,115 | $8.16 | $343.7K | $10.00M | 1 | 2014-02-05 |
| HUMANIGEN, INC (KBIO) Delisted | 579,030 | — | — | $700.0K | 1 | 2013-02-07 | |
| GENZ | 10%+ Owner | 187,986,225 | $38.13 | $7.17B | $2.48B | 1 | 2011-04-08 |
Recent Filings
68 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-08-12 | Latigo Biotherapeutics, Inc. (LTGO) Delisted | Conv (C) | +672,778 | $0 | EDGAR |
| 2026-08-07 | ATTO | Mixed | +1,082,855 | $5.10M | EDGAR |
| 2026-08-07 | ATTO | Mixed | +1,082,855 | $5.10M | EDGAR |
| 2021-09-14 | Translate Bio, Inc. (TBIO) Delisted | Buy (P) | +71,983,597 | $2.74B | EDGAR |
| 2021-08-02 | Icosavax, Inc. (ICVX) Delisted | Mixed | +3,155,169 | $1.00M | EDGAR |
| 2020-07-29 | Inozyme Pharma, Inc. (INZY) Delisted | Mixed | +520,125 | $1.30M | EDGAR |
| 2020-06-11 | REGN | Sell (S) | −120,234 | -$71.84M | EDGAR |
| 2020-05-29 | REGN | Sell (S) | −22,821,451 | -$11.64B | EDGAR |
| 2020-03-11 | REGN | Sell (S) | −128,914 | -$63.12M | EDGAR |
| 2019-09-12 | REGN | Sell (S) | −172,904 | -$48.61M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.